Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 2952

1.

[Intraoperative intraperitoneal chemoperfusion treatment with cisplatin and dioxadet on a model of peritoneal carcinomatosis in ovarian cancer: safety and efficacy evaluation].

Bespalov VG, Kireeva GS, Belyaeva OA, Senchik KY, Stukov AN, Gafton GI, Soloviev LA, Vasilchenko MV, Guseinov KD, Alexeev VV, Belyaev AM.

Vopr Onkol. 2015;61(4):647-52. Russian.

PMID:
26571838
2.

Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.

Ajgal Z, Chapuis N, Emile G, Cessot A, Tigaud JM, Huillard O, Boudou-Rouquette P, Fontenay M, Goldwasser F, Alexandre J.

Cancer Chemother Pharmacol. 2015 Nov;76(5):1033-9. doi: 10.1007/s00280-015-2875-8. Epub 2015 Sep 29.

PMID:
26420236
3.

Bevacizumab, Carboplatin and Paclitaxel Combination Treatment in Advanced Stage Ovarian Cancer: The First Experience in Thammasat University Hospital, Thailand: A Case Report.

Suwannarurk K, Thaweekul Y, Mairaing K, Poomtavorn Y, Tangtiang K, Piyawang W, Bhamarapravatana K.

J Med Assoc Thai. 2015 Apr;98 Suppl 3:S121-5.

PMID:
26387399
5.

Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).

Seifert H, Georgiou A, Alexander H, McLachlan J, Bodla S, Kaye S, Barton D, Nobbenhuis M, Gore M, Banerjee S.

Gynecol Oncol. 2015 Nov;139(2):216-20. doi: 10.1016/j.ygyno.2015.08.015. Epub 2015 Aug 28.

PMID:
26318078
6.

[A Case of Pneumocystis Pneumonia during Chemotherapy for Recurrent Ovarian Cancer].

Shiomi M, Okubo R, Miyagi K, Murakami J, Kuwaduru T, Uragami K, Nakagawa M, Yoshioka E, Tsuruta T, Tashima R, Hori K, Ito K.

Gan To Kagaku Ryoho. 2015 Jul;42(7):879-81. Japanese.

PMID:
26197755
7.
8.

Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma: A Retrospective Study of 164 Cases.

Bai H, Sha G, Cao D, Yang J, Chen J, Wang Y, Lang J, Shen K, Zhang Z.

Medicine (Baltimore). 2015 Jul;94(27):e1121. doi: 10.1097/MD.0000000000001121.

9.

Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.

Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, Le ND, Gilks CB, Singh N.

J Clin Oncol. 2015 Aug 1;33(22):2457-63. doi: 10.1200/JCO.2014.60.5212. Epub 2015 Jun 29.

PMID:
26124480
10.

Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.

Stringer-Reasor EM, Baker GM, Skor MN, Kocherginsky M, Lengyel E, Fleming GF, Conzen SD.

Gynecol Oncol. 2015 Sep;138(3):656-62. doi: 10.1016/j.ygyno.2015.06.033. Epub 2015 Jun 24.

PMID:
26115975
11.

Chemotherapeutic treatment of colorectal cancer in pregnancy: case report.

Makoshi Z, Perrott C, Al-Khatani K, Al-Mohaisen F.

J Med Case Rep. 2015 Jun 13;9:140. doi: 10.1186/s13256-015-0621-9.

12.

Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group.

Vergote I, Debruyne P, Kridelka F, Berteloot P, Amant F, Honhon B, Lybaert W, Leunen K, Geldhof K, Verhoeven D, Forget F, Vuylsteke P, D'Hondt L, Huizing M, Van den Bulck H, Laenen A.

Gynecol Oncol. 2015 Aug;138(2):278-84. doi: 10.1016/j.ygyno.2015.05.042. Epub 2015 Jun 4.

PMID:
26049123
13.

Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer.

Tran AQ, Cohen JG, Li AJ.

Gynecol Oncol. 2015 Aug;138(2):263-6. doi: 10.1016/j.ygyno.2015.05.035. Epub 2015 May 30.

PMID:
26037901
14.

[Individualized therapy of synchronous ovarian and colon cancers with lymph].

Deme D, Bishr AM, Nizar J, Telekes A.

Orv Hetil. 2015 Jun 7;156(23):939-43. doi: 10.1556/650.2015.30169. Hungarian.

PMID:
26027602
15.

MicroRNA regulation of RAD51 in serous ovarian cancer modulates chemotherapy response.

Wiemer EA, Berns EM.

J Natl Cancer Inst. 2015 May 20;107(7). pii: djv161. doi: 10.1093/jnci/djv161. Print 2015 Jul. No abstract available.

PMID:
25995443
16.

Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.

Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W.

J Natl Cancer Inst. 2015 May 20;107(7). pii: djv108. doi: 10.1093/jnci/djv108. Print 2015 Jul.

PMID:
25995442
17.

Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.

Favero G, Macerox N, Pfiffer T, Köhler C, da Costa Miranda V, Estevez Diz Mdel P, Fukushima JT, Baracat EC, Carvalho JP.

Oncology. 2015;89(3):159-66. doi: 10.1159/000381462. Epub 2015 May 1.

PMID:
25968072
19.

Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients.

Liutkauskiene S, Janciauskiene R, Jureniene K, Grizas S, Malonyte R, Juozaityte E.

BMC Cancer. 2015 Mar 7;15:105. doi: 10.1186/s12885-015-1104-5.

20.

Primary peritoneal cancer: study of 14 cases and comparison with epithelial ovarian cancer.

Fukuda T, Imai K, Yamauchi M, Teramae M, Hashiguchi Y, Ichimura T, Yasui T, Sumi T.

Eur J Gynaecol Oncol. 2015;36(1):49-53.

PMID:
25872334
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk